Moonwalk Biosciences is developing adipose-targeted siRNA medicines for obesity and cardiometabolic disease. Its lead programs are designed to alter fat-tissue pathways while limiting effects on other tissues, with the lead obesity candidate in IND-enabling development ahead of planned human testing in 2027.
GV
Gaorong Ventures
Activity from announced rounds
Activity in this selectionNorth America
Gaorong Ventures, also identified as Gaorong Capital, is the investment organization connected to Axoft and Moonwalk financing histories.
Recorded funding activity
Moonwalk develops medicines targeting fat-tissue pathways, while Axoft develops implanted brain-computer interfaces. The recorded activity also includes Anew’s combination of molecular models and experimental biology for drug discovery. These companies pursue different clinical technologies.
- Rounds participated in
- 3
- Confirmed lead rounds
- 0 1 roles undisclosed
- New companies
- 3 First participation on record · 0 follow-on
- Funding in participating rounds
- $1B 3 disclosed · full round size, not this investor’s share
By stage
By primary sector
By country
Rounds
3 in this selectionMoonwalk Biosciences
$70MSeries B
ParticipantDogotix Inc. (XPeng Robotics)
Dogotix Inc. is the holding company for XPeng’s robotics business, which develops humanoid and other general-purpose robotic systems.
$900MConditional Series A subscription agreements
ParticipantAxoft
Develops implantable Brain-Computer Interfaces (iBCIs) for neurological disorders
$55MSeries A
Role not disclosed